People in England who have already had a heart attack, stroke, or serious circulation problems in their legs, and who are overweight, could soon be offered a weekly semaglutide injection on the NHS as part of a new approach to preventing further cardiovascular events. NICE said its independent committee has recommended the treatment for adults with cardiovascular disease and a body mass index of at least 27 kg/m², with the decision announced on 1 April 2026. NICE recommendation
The drug, better known by the brand name Wegovy, is already used for weight management, but this new recommendation is specifically about reducing the risk of major adverse cardiovascular events. NICE said it should be offered alongside a reduced-calorie diet and increased physical activity, and on top of medicines patients may already be taking, such as statins. NHS England said the move could make the treatment available to around 1.2 million people over the next few years.
A treatment aimed at prevention, not only weight loss
According to NICE, the evidence from a clinical trial showed semaglutide reduced the risk of heart attack, stroke, or cardiovascular death, with the benefit seen early in the study, before significant weight loss occurred. That finding suggests the medicine may work directly on the heart and blood vessels, rather than only through changes in body weight.
NHS England said semaglutide is already available on the NHS in England for people with obesity through specialist weight management services, and that Ozempic, another brand name for semaglutide, is widely prescribed for type 2 diabetes. In its announcement, the health service described the latest recommendation as part of its wider effort to prevent and manage long-term conditions more effectively. NHS England announcement
Diet and lifestyle still remain part of the plan
Although the injection is being positioned as a major new tool for high-risk patients, both NICE and NHS England stressed that it is not a standalone solution. The recommendation places the medicine alongside a healthy or reduced-calorie diet and increased physical activity, reflecting the continued importance of lifestyle measures in cardiovascular care.
NHS England’s cardiovascular prevention lead, Helen Williams, said the treatment could be life-changing for people at high risk of another event, while the British Heart Foundation said medicines like semaglutide are now considered important beyond their effect on the scales. The broader message from the guidance is that medical treatment and nutrition remain closely linked in prevention strategies, especially for people already living with cardiovascular disease.
For the NHS, the recommendation also adds another high-profile use case for GLP-1 medicine in an era when demand for weight and cardiometabolic treatments is rising. NICE said its decision was based on clinical effectiveness and value for NHS resources, while NHS England described the deal as a way to make the treatment cost-effective for the health service.
For patients, the practical impact will depend on how quickly services can implement the guidance and how clinicians prioritise eligible groups. But with cardiovascular disease still one of the country’s biggest killers, the new recommendation signals a significant shift in how the NHS may use weight-related medicines to support prevention, alongside dietary change and physical activity.
Sursa foto: Imagine generată AI
